[4-(2-Amino-3-sulfanylpropyl)-3-butylpiperazin-1-yl]-naphthalen-1-ylmethanone

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: [4-(2-Amino-3-sulfanylpropyl)-3-butylpiperazin-1-yl]-naphthalen-1-ylmethanone
• 化学式: C₂₂H₃₁N₃OS
• 分子量: 385.6
• InChiKey: BICXECMCJCNEDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  50.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• METHODS OF TREATMENT OF OCULAR NEOVASCULARIZATION
  申请人：——

  公开号：US20020006967A1

  公开（公告）日：2002-01-17

  The present invention includes methods for treatment and prophylaxis of eye disorders and injuries, particularly treatment and prophylaxis of ocular neovascularization and disorders, especially a vasculopathy that affects retinal or chorodial vessels. The methods of the invention in general comprise administration of a therapeutically effective amount of a compound that inhibits farnesyl-protein transferase to a subject suffering from or susceptible to ocular neovascularization or associated disorder.

  本发明包括治疗和预防眼部疾病和损伤的方法，特别是治疗和预防眼部新生血管和疾病，尤其是影响视网膜或脉络膜血管的血管病变。本发明的方法一般包括向患有或易患眼部新生血管或相关疾病的受试者施用治疗有效量的抑制法尼基蛋白转移酶的化合物。
• Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein
  申请人：SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.)

  公开号：US20030162786A1

  公开（公告）日：2003-08-28

  The invention relates to the use of cysteine derivatives for preparing a medicament intended to treat diseases which result from the formation of the heterotrimeric G protein. These diseases include in particular diseases linked to the following biological functions or disorders: smell, taste, perception of the light, neurotransmission, neurodegeneration, endocrine and exocrine gland functions, autocrine and paracrine regulation, arterial tension, embryogenesis, benign cell proliferation, oncogenesis, viral infection, immunological functions, diabetes, obesity, and benign and malign proliferative diseases. Said cysteine derivatives include in particular: bis-1,1′-[7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine disulphide (I), and bis-1,1′-7-(2-amino-1-oxo-3-thiopropyl-(2-(1-naphtyl)-8-(2-methylpropyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazin-7-yl) disulphide (II).

  本发明涉及使用半胱氨酸衍生物制备药物，用于治疗因形成异三聚 G 蛋白而导致的疾病。这些疾病尤其包括与下列生物功能或紊乱有关的疾病：嗅觉、味觉、对光的感知、神经传递、神经变性、内分泌腺和外分泌腺功能、自分泌和旁分泌调节、动脉张力、胚胎发育、良性细胞增殖、肿瘤发生、病毒感染、免疫功能、糖尿病、肥胖症以及良性和恶性增殖性疾病。 所述半胱氨酸衍生物尤其包括 双-1,1′-[7-(2-氨基-1-氧代-3-硫代丙基)-8-(环己基甲基)-2-(2-甲氧基苯基)-5,6,7,8-四氢咪唑[1.2a]吡嗪二硫化物 (I)，以及 双-1,1′-7-(2-氨基-1-氧代-3-硫代丙基-(2-(1-萘基)-8-(2-甲基丙基)-5,6,7,8-四氢咪唑[1.2a]吡嗪-7-基)二硫化物(II)。
• EP0840605A4
  申请人：——

  公开号：EP0840605A4

  公开（公告）日：2000-05-10
• COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
  申请人：MERCK & CO., INC.

  公开号：EP0836383A1

  公开（公告）日：1998-04-22
• COMPOUNDS USEFUL IN THE TREATMENT OF NEUROFIBROMATOSIS
  申请人：University of Cincinnati

  公开号：EP0840605A1

  公开（公告）日：1998-05-13